We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Editas Medicine Inc. (EDIT - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in EDIT.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 3 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of $2.07 a share a month ago to its current level of a loss of $2.60.
Also, for the current quarter, Editas Medicine has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 64 cents a share from a loss of 57cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 29.1% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical-Biomedical/Genetics industry, you may instead consider a better-ranked stock - ANI Pharmaceuticals, Inc. (ANIP - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Makes Editas Medicine (EDIT) a Strong Sell?
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Editas Medicine Inc. (EDIT - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in EDIT.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 3 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of $2.07 a share a month ago to its current level of a loss of $2.60.
Also, for the current quarter, Editas Medicine has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 64 cents a share from a loss of 57cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 29.1% in the past month.
EDITAS MEDICINE Price and Consensus
EDITAS MEDICINE Price and Consensus | EDITAS MEDICINE Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical-Biomedical/Genetics industry, you may instead consider a better-ranked stock - ANI Pharmaceuticals, Inc. (ANIP - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>